Universal influenza vaccine
Ended Awarded Last action
- Contract number
- 75N93022F00003
- Awardee
-
Charles River Laboratories, Inc. UEI NAPSK1UAMAE5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,006,234
Award facts
- Contract value 100% obligated
- $2,006,234.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Wilmington, MA 01887, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$30 | |
| Funding Only Action | -$619,728 | |
| Change Order | $1,250,588 | |
| Other Administrative Action | $0 | |
| Original award | $1,375,404 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order to Charles River Laboratories, Inc. for universal influenza vaccine development support under the FY 2026 Undefined Delivery Order (UDO) Initiative. The contract, valued at approximately $2.0M, operates under a firm fixed-price delivery order model with a completion date of September 11, 2025. This modification primarily serves to de-obligate excess funds from the existing arrangement. The work will be performed at Charles River's facility in Wilmington, Massachusetts, and no small business set-aside designation was applied to this award.
Charles River Laboratories, a global contract research organization headquartered in Wilmington, Massachusetts, is well-positioned to execute this scope given its extensive experience supporting federal vaccine development initiatives. The company has previously provided vaccine candidate preparation, characterization, challenge virus production, and universal vaccine development services to government agencies, demonstrating specialized capabilities directly aligned with NIAID's mission. As a critical partner to the National Institutes of Health and its constituent institutes across multiple therapeutic areas, Charles River maintains multiple indefinite delivery contracts and blanket purchase agreements totaling hundreds of millions of dollars, reflecting its established standing as a primary federal contractor in biomedical research support services.
Quick answers
Who was awarded contract 75N93022F00003?
75N93022F00003 was awarded to Charles River Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 12, 2022.
How much is contract 75N93022F00003 worth?
The government has obligated $2,006,234 on 75N93022F00003.
Is contract 75N93022F00003 an order under another contract?
Yes. 75N93022F00003 is a delivery order under 75N93021D00018, an indefinite delivery contract.
Was contract 75N93022F00003 competed?
The extent of competition for 75N93022F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award